| Dr Steven Lee Perkins, MD | |
|
2900 16th St, Bedford, IN 47421-3510 | |
| (812) 676-4102 | |
| (812) 676-4106 |
| Full Name | Dr Steven Lee Perkins |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 15 Years |
| Location | 2900 16th St, Bedford, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730315953 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 01069971A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health Bedford Hospital | Bedford, IN | Hospital |
| Indiana University Health Paoli Hospital | Paoli, IN | Hospital |
| Witham Health Services | Lebanon, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indiana University Health Southern Indiana Physicians Llc | 6204748197 | 449 |
| Witham Memorial Hospital | 4082523170 | 88 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Entity Name | Little Company Of Mary Hospital Of Indiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114120128 PECOS PAC ID: 4587578042 Enrollment ID: O20031118000733 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Entity Name | Indiana University Health Southern Indiana Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013953983 PECOS PAC ID: 6204748197 Enrollment ID: O20040423000556 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Entity Name | Union Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013965573 PECOS PAC ID: 8426943614 Enrollment ID: O20040519000807 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Entity Name | Witham Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083750293 PECOS PAC ID: 4082523170 Enrollment ID: O20040519001402 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Entity Name | St Vincent Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144513375 PECOS PAC ID: 7012047640 Enrollment ID: O20100609000045 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Entity Name | Hospital Medicine Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528433802 PECOS PAC ID: 9234432881 Enrollment ID: O20160714001751 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Entity Name | Clarksville Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811629546 PECOS PAC ID: 3476937756 Enrollment ID: O20220906001693 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Lee Perkins, MD 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Steven Lee Perkins, MD 2900 16th St, Bedford, IN 47421-3510 Ph: (812) 676-4102 |
News Archive
Oral administration of a commensal gut microbe, Faecalibacterium prausnitzii, improves fatty liver in mice. F. prausnitzii is considered one of the most important bacterial indicators of a healthy gut.
Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
Surgical errors are a fact of life – and death - in operating rooms and hospitals around the country. According to a major university study, foreign objects are left inside a patient 39 times a week, and surgeries are performed on the wrong side or site of a patient another 20 times a week. While all U.S. hospitals are working diligently to eliminate these events – called "never events" or "serious reportable adverse events" – some, like Kaiser Permanente, have had much more success than others.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 6 days ago
Dr. Theresa Ann Travis, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2516 Q St, Suite B, Bedford, IN 47421 Phone: 812-275-3328 Fax: 812-279-5977 | |
Tassawar Hussain, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 16th St, Indiana University Health Bedford Hospital, Bedford, IN 47421 Phone: 812-278-8800 Fax: 812-275-1343 | |
Mrs. Cristina Bickford, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 W. 16 Th Street, Bedford, IN 47421 Phone: 812-278-8800 Fax: 812-275-1343 | |
Hojjat Shamloo, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 W 16th Street, Bedford, IN 47421 Phone: 812-278-8800 Fax: 812-275-1359 | |
Joanne Smart, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 W 16th Street, Bedford, IN 47421 Phone: 812-278-8800 Fax: 812-275-1343 | |
Kamal Girgis, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 W 16th Street, Bedford, IN 47421 Phone: 812-278-8800 Fax: 812-275-1359 | |
Dr. Pratap Singh, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2520 Q St, Suite B, Bedford, IN 47421 Phone: 812-278-8000 Fax: 812-278-8110 |